Cara Therapeutics, Inc. Share Price Berne S.E.

Equities

69C

US1407551092

Pharmaceuticals

Delayed Berne S.E. 5-day change 1st Jan Change
- CHF -.--% Intraday chart for Cara Therapeutics, Inc. -.--% -.--%

Financials

Sales 2024 * 6.41M 5.73M 507M Sales 2025 * 7.39M 6.6M 585M Capitalization 15.15M 13.52M 1.2B
Net income 2024 * -72M -64.29M -5.69B Net income 2025 * -44M -39.29M -3.48B EV / Sales 2024 * 5.71 x
Net Debt 2024 * 21.5M 19.2M 1.7B Net Debt 2025 * 78.9M 70.45M 6.24B EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
-0.22 x
P/E ratio 2025 *
-0.38 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.75%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 54 05/08/18
Director of Finance/CFO 54 11/09/22
Compliance Officer 61 31/10/16
Members of the board TitleAgeSince
Chairman 60 30/06/10
Director/Board Member 73 15/07/14
Director/Board Member 58 01/08/23
More insiders
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
0.277 USD
Average target price
1.65 USD
Spread / Average Target
+495.67%
Consensus